Senate Democrats press AstraZeneca, Sanofi on RSV antibody shortage

As RSV cases start to rise this season, AstraZeneca and Sanofi have struggled to match the demand for their new monoclonal antibody to protect against RSV — and several Democrat senators are asking the two companies to explain what’s causing the supply holdup.

The FDA in…
Click here to view original post